LAUSR

Key Points Question Is maintenance therapy after first-line treatment of ovarian cancer cost-effective in the United States? Findings In this economic evaluation of maintenance strategies after first-line ovarian cancer therapy, no maintenance regimen—including olaparib, olaparib-bevacizumab, bevacizumab, and niraparib—was cost-effective when using a willingness-to-pay threshold of $100 000 per progression-free life-year saved, even when stratified by molecular signatures. Olaparib monotherapy became cost-effective for patients with a BRCA variant when current olaparib pricing was reduced by half. Meaning Various frontline maintenance therapies for ovarian cancer may have clinical benefit but may not be considered cost-effective, even with reductions in drug pricing.